Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

Thrombolysis May Be OK for DOAC-Treated Patients With Ischemic Stroke

News Daily News

Thrombolysis May Be OK for DOAC-Treated Patients With Ischemic Stroke

January 07, 2026

Cardiology Consults Tied to Better Outcomes in Patients With HF

News Conference News ESC Heart Failure 2025

Cardiology Consults Tied to Better Outcomes in Patients With HF

May 19, 2025

AHA Statement Zeroes In On Sleep Health

News Daily News

AHA Statement Zeroes In On Sleep Health

April 17, 2025

January 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

January 24, 2025

October 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

October 2024 Dispatch for the CV Team

October 25, 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

August 30, 2024

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

News Daily News

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

Michael O'Riordan

June 23, 2023

TCTMD’s Top 10 Most Popular Stories for June 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2022

July 04, 2022

Dapagliflozin Boosts Health Status Across LVEF Range

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

May 23, 2022

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

May 03, 2022

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

News Daily News

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

April 20, 2022

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

News Conference News ESC 2021

EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF

August 27, 2021

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

News Daily News

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

August 04, 2021

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

News Daily News

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Michael O'Riordan

April 02, 2021

Did Regional Differences Muddy Results in COMMANDER-HF?

News Daily News

Did Regional Differences Muddy Results in COMMANDER-HF?

February 04, 2021

News Industry News

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

June 26, 2019

Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’

News Daily News

Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’

September 13, 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.